The NHS has become the first in the world to roll out ‘revolutionary’ blood tests to help treat cancer patients.
Tens of thousands of patients with lung and breast cancer in England are set to benefit from the new ‘liquid biopsy’ test that can speed up access to targeted therapy by up to two weeks earlier, all while helping some patients avoid further tests and treatments – including chemotherapy.
The test is to be used before traditional tissue biopsies to help diagnose certain types of cancer.
A ‘liquid biopsy’ works by detecting tiny fragments of circulating tumour DNA (ctDNA) and looks for specific genetic variations of cancer, allowing patients to access targeted therapies which are tailored to the genetic profile of their cancer.
The blood test is being rolled out nationwide following a successful pilot, and NHS England expects that around 15,000 patients with suspected lung cancer could now benefit from the test each year.
ADVERTISEMENT
Thousands of patients with cancer will benefit from a new blood test which can speed up access to targeted therapy.
Pilot data in lung cancer showed that in some cases, patients received the results of ctDNA testing needed to make treatment decisions 16 days earlier with liquid biopsies compared with the standard cancer tissue biopsy approach.
An independent health economic assessment of the pilot estimated the test could save the NHS up to £11 million per year in lung cancer care.
ADVERTISEMENT
Because of this, the NHS says it’s now looking at using the test in a range of other cancers too – including pancreatic and gallbladder cancer.
“Liquid biopsies are leading us into a new era of personalised cancer care,” commented Professor Peter Johnson, who is the NHS’s national clinical director for cancer, “and it’s fantastic that we are now able to expand the use of this revolutionary test on the NHS to help tailor treatment for thousands of patients across the country.
The NHS has become the first in the world to roll out a ‘revolutionary’ blood test to help treat cancer patients / Credit: Wikimedia Commons | Pexels
“Cutting-edge genomic testing is helping us deliver more targeted and kinder care for patients, enabling some to avoid more intensive treatments such as further chemotherapy, which can have a huge impact.
ADVERTISEMENT
“We are already seeing the difference this test can make in lung and breast cancer, and we hope to roll it out for patients with other forms of cancer in the near future.
“As research progresses, it’s exciting that this approach has the potential to help us ‘scan’ the body in a single blood test to see where and how cancer may be developing and target it with speed and precision to help save more lives.”
More than 1,600 patients with suspected lung cancer and around 600 advanced breast cancer patients have had liquid biopsy tests done since April, but the test is now available for all eligible lung and breast cancer patients in NHS hospitals across England.
Featured Image – Karolina Grabowska (via Pexels)
News
NHS launches new AI and robot cancer detection pilot offering ‘glimpse into future’
Emily Sergeant
The NHS has launched a ‘trailblazing’ new AI and robot pilot to help spot cancers sooner.
Patients who are facing suspected lung cancer could get answers sooner under the new pilot that makes use of artificial intelligence (AI) and robotic technology to help doctors reach hard-to-detect cancers earlier, and all without with fewer tests too.
At the moment, patients are faced with weeks of repeat scans and procedures to come to a diagnosis.
But this could soon be replaced with a single, half-hour cancer biopsy – reducing prolonged uncertainty, and avoiding more invasive surgery.
According to the NHS, the new approach uses AI software to rapidly analyse lung scans and flag small lumps that are most likely to be cancerous, before a robotic camera is then used to guide biopsy tools through the airways with much greater precision than standard techniques.
A new NHS pilot using AI and robotic technology will help doctors reach hard-to-detect lung cancers earlier.
Weeks of scans and procedures could be replaced with a single biopsy, reducing uncertainty and avoiding more invasive surgery.
The robot can reach nodules as small as 6mm – which is around the size of a grain of rice – that are hidden deep in the lung and are often deemed too risky or difficult to access using existing methods, and once AI has highlighted higher-risk areas, doctors can then take a precise tissue sample, which is sent to specialist laboratories and reviewed by expert cancer teams to confirm or rule out cancer.
The NHS’s top cancer doctor hailed the pilot – which is currently being carried out at Guy’s and St Thomas’ NHS Foundation Trust – as ‘a glimpse of the future of cancer detection’.
“Waiting to find out if you might have cancer is incredibly stressful for patients and their families,” admitted Professor Peter Johnson, who is NHS England’s National Clinical Director for Cancer.
The NHS has launched a new AI and robot cancer detection pilot that’s offering a ‘glimpse into future’ / Credit: rawpixel
“Our lung cancer screening programme means that we are picking up more cancers at an early stage than ever, and by bringing AI and robotics together in this trailblazing NHS pilot, we’re bringing in the very latest technology to give clinicians a clearer look inside the lungs and support faster, more accurate biopsies.
“This is a glimpse of the future of cancer detection.
“Innovation like this is exactly how we can help diagnose more cancers faster, so treatment can be most effective, and why the NHS continues to lead the way in bringing new technology safely into frontline care.”
If successful, the pilot will help the NHS to generate evidence to develop a national commissioning policy for robotic bronchoscopy.
It will also support more consistent access to the technology across the NHS in future.
Featured Image – Tima Miroshnichenko (via Pexels)
News
Chester Zoo announces new spring date for its popular running event to help UK wildlife
Emily Sergeant
Chester Zoo has announced that its popular Run For Nature is back again this year, and this time, there’s a new spring edition.
The UK’s biggest charity zoo seen success with this event in the past few years, with thousands of runners signing up for one of the North West’s most unique athletic experiences and all funds raised going towards efforts to protect highly-endangered giraffes in Africa.
This year though, the much-loved event’s focus brings conservation ‘a little closer to home’ and will protect some of the UK’s most threatened species instead – with all funds helping to safeguard hedgehogs, kingfishers, otters, harvest mice, and more.
It comes as the UK is currently considered one of the most nature-depleted countries on Earth.
Participants will first get to wind through the zoo and enjoy glimpses of elephants, lemurs, and other incredible species along the way, before heading out into the picturesque Cheshire countryside.
Adults can choose from a 10K or 5K route, while younger runners are invited to take part in a one-mile ‘Zoom’ race, open to children aged four-15, which takes place entirely within the zoo’s incredible 130-acre grounds.
All runners will receive free entry to the zoo for the rest of the day as part of their registration, along with a 25% discount for friends and family who come along to show support.
Chester Zoo’s popular 10K charity run is returns with a new spring date / Credit: Chester Zoo
Lorraine Jubb, who is the Fundraising Lead at Chester Zoo, called the Run For Nature a ‘really special event’.
“In previous years, runners have already supported conservation efforts for Asian elephants, Eastern black rhinos and Northern giraffe,” she explained. This springtime though, we’re turning our attention much closer to home in the UK, and to the wildlife we share our gardens, parks and countryside with.
“With one in six species now at risk of extinction in the UK, every runner will be playing a vital role in helping us protect animals and supporting our growing nature recovery work across right across Cheshire.
Emily Sergeant -
2nd June 2025 
